The competition among drugs for binding to plasma proteins is regarded as a pharmacokinetic drug interaction. Competition between antitumor agents and other drugs for plasma protein binding can alter the free concentration of the drug, potentially impacting its efficacy and increasing the risk of toxic side effects. Through a range of spectroscopic techniques, this study examined the interaction between limonin and human serum albumin (HSA) in the context of berberine (Ber) and curcumin (Cur) under physiological conditions to clarify the binding mechanisms of binary and ternary systems at the molecular level. As demonstrated by fluorescence quenching experiments, Static quenching was identified as the mechanism of interaction between HSA and limonin. The results of site competition experiments indicated that the binding site between limonin and HSA was site I, a result further supported by molecular docking simulations. Through the use of thermodynamic data calculations, it was determined that limonin forms a stable complex with HSA by establishing hydrogen bonds and van der Waals forces. Circular dichroism (CD) spectroscopy, three-dimensional (3D) fluorescence spectroscopy, and synchronous fluorescence spectroscopy (SFS) employed to validate the notion that limonin perturbed the microenvironment of amino acids and induced conformational changes in HSA. What's more, the presence of Ber or Cur was found to have further modified the alterations observed in the interaction between the original HSA-limonin binary system. In vitro cellular experiments showed that interaction with HSA reduced the antitumor activity of limonin. In contrast, adding Ber or Cur increased the inhibition rate of tumor cells. The coexistence of both Ber and Cur significantly diminished limonin's binding affinity to HSA. The current investigation enhances comprehension regarding the binding characteristics and interaction mechanisms involving limonin, Ber, Cur, and HSA. It explores the potential of HSA as a versatile drug carrier and furnishes theoretical underpinnings for co-administrative strategies.

2024-11-12·Langmuir

A Newly Predicted Magnetic TMB6 Monolayer for Efficient Nitrogen Fixation

Article

作者: Ji, Zhiheng ; Zhang, Xiuyun ; Duan, Yuanyuan ; Yao, Xiaojing ; Meng, Lijuan ; Sun, Yi ; Sun, Jinxin ; Chen, Anjie

Developing electrocatalysts for the N₂ reduction reaction (NRR) with high activity, high selectivity, and low cost is urgently required to enhance the NH₃ yield rate. Based on first-principles calculations, we predict a series of new transition metal boride TMB₆ (TM = Ti, V, Cr, Mn, Fe, and Co) monolayers and investigate their magnetoelectronic and electrocatalytic properties. The results reveal that VB₆ and CoB₆ favor ferromagnetic coupling, while TiB₆, CrB₆, MnB₆, and FeB₆ display antiferromagnetic ordering. Furthermore, TiB₆ exhibits a high Néel temperature of 344 K and a large magnetic anisotropy energy of 614 μeV per Ti atom. Most interestingly, TiB₆ and VB₆ exhibit superior NRR catalytic activity with a limiting potential of -0.50 and -0.19 V, respectively, and favorable NRR selectivity over the HER. Finally, the structural stability of TMB₆ monolayers has been confirmed by a set of phonon dispersion, molecular dynamics, and elastic constant calculations. Our results highlight the use of the newly designed two-dimensional (2D) TM borides as promising candidates for spintronic devices and nitrogen fixation applications.

2024-11-01·Medicine

Improved injection site reactions after switching from adalimumab reference to adalimumab biosimilar LBAL for ulcerative colitis: A case report

Article

作者: Hirakawa, Yudai ; Yoshiura, Masato ; Kikkawa, Nao ; Kakiuchi, Toshihiko

Rationale:Adalimumab (ADA) is an antitumor necrosis factor agent that is used for the treatment of inflammatory bowel disease. However, its cost has resulted in varying degrees of restricted access across global healthcare economies. Biosimilars are agents that contain a similar version of the active substance of an already approved original biologic agent and are intended to be used for the same indication as the reference product. In general, biosimilars follow the originator; therefore, information on its efficacy and safety had been few. Some studies have reported on replacement of the originator with a biosimilar of the same efficacy because of medical reasons.Patient concerns:A 15-year-old girl with steroid-dependent ulcerative colitis that relapsed after vedolizumab was treated with ADA reference. Six weeks after starting ADA reference, her gastrointestinal symptoms had completely resolved, however, immediately after the eighth dose of ADA reference, redness, swelling, and pruritus were noted at the injection site on the left thigh.Diagnosis:Allergic reaction caused by the ADA reference.Intervention:ADA reference was changed to ADA biosimilar LBAL.Outcomes:ADA biosimilar LBAL was continued without any symptoms, such as local swelling, redness, or itching. In addition, there was no deterioration of gastrointestinal symptoms.Lessons:We showed the efficacy and safety of ADA biosimilar LBAL as an alternative to ADA reference, which caused injection site reactions. Changing from ADA reference to ADA biosimilar because of adverse events may be an option that needs careful observation, considering that the originator and the biosimilar are not exactly the same.

100 项与 Antitumor agents(Athersys, Inc.) 相关的药物交易

登录后查看更多信息